Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E. Langley, Mahesh Parmar, S.K. Sundaram et al.|The Lancet|2021Cited by 49
Patients’ Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER StudyMartin J. Connor, Verity Watson, Mesfin G. Genie et al.|European Urology Oncology|2024Cited by 4
Metastatic prostate cancer men’s attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment studyMartin J. Connor, Hashim U. Ahmed, Mesfin G. Genie et al.|BMJ Open|2021Cited by 3
Metastatic prostate cancer patients’ Attitudes towards Treatment of the local Tumour and metastasis Evaluative Research (IP5-MATTER): A multicentre, discrete choice experiment trial-in-progressMartin J. Connor, Hashim U. Ahmed, Mesfin G. Genie et al.|European Urology|2021Cited by 1